The Role of FasL and Fas in Health and Disease
The Role of FasL and Fas in Health and Disease
复制标题
DOI：
10.1007/978-0-387-89520-8_5
复制
发表时间：
2009-01-01
期刊：
影响因子：
--
通讯作者：
Wajant, Harald
中科院分区：
文献类型：
--
作者：
Ehrenschwender, Martin;Wajant, Harald
FS7 相关细胞表面抗原（Fas，也称为 CD95、APO-1 或 TNFRSF6）自 1989 年被发现以来，引起了细胞凋亡研究领域的极大兴趣。Shin Yonehara 和 Peter Krammer 小组首次报道了用 Fas 特异性单克隆抗体处理细胞后广泛诱导细胞凋亡。(1,2) Fas(3) 及其配体的克隆，(4,5) FasL（也称为CD178、CD95L 或 TNFSF6）为建立该受体-配体系统作为哺乳动物细胞凋亡的中心调节剂奠定了基石。 FasL-Fas 介导的细胞毒性的治疗性利用很快成为一个雄心勃勃的目标，并且在过去十年中，已经开发了许多策略来实现这一目标。在本章中，我们将简要介绍 FasL-Fas 系统的基本概况，然后回顾其生理和病理生理学相关性。最后，将讨论 FasL-Fas 相关的治疗工具和概念。
The FS7-associated cell surface antigen (Fas, also named CD95, APO-1 or TNFRSF6) attracted considerable interest in the field of apoptosis research since its discovery in 1989. The groups of Shin Yonehara and Peter Krammer were the first reporting extensive apoptotic cell death induction upon treating cells with Fas-specific monoclonal antibodies.(1,2) Cloning of Fas(3) and its ligand,(4,5) FasL (also known as CD178, CD95L or TNFSF6), laid the cornerstone in establishing this receptor-ligand system as a central regulator of apoptosis in mammals. Therapeutic exploitation of FasL-Fas-mediated cytotoxicity was soon an ambitous goal and during the last decade numerous strategies have been developed for its realization. In this chapter, we will briefly introduce essential general aspects of the FasL-Fas system before reviewing its physiological and pathophysiological relevance. Finally, FasL-Fas-related therapeutic tools and concepts will be addressed.